Dectrekumab (QAX576), a humanized monoclonal antibody targeting IL-13, significantly reduces intraepithelial esophageal eosinophil counts and normalizes dysregulated esophageal disease-related transcripts in Eosinophilic esophagitis (EoE), offering sustained benefits. It is valuable for inflammation and immunology research [1].